Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephal...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nancy L Monson, Petra Cravens, Rehana Hussain, Christopher T Harp, Matthew Cummings, Maria de Pilar Martin, Li-Hong Ben, Julie Do, Jeri-Anne Lyons, Amy Lovette-Racke, Anne H Cross, Michael K Racke, Olaf Stüve, Mark Shlomchik, Todd N Eagar
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2011
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/7eb457a109ad42ca8f3e5a28c0d1260d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/7eb457a109ad42ca8f3e5a28c0d1260d

Ejemplares similares